These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3943113)

  • 1. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methodology and limitations of pre-clinical models for the development of anticarcinogenic chemotherapy combinations].
    Vassal G
    Bull Cancer; 1998 Nov; 85(11):929-34. PubMed ID: 9951420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
    Carter WH
    Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
    Corbett TH; Griswold DP; Wolpert MK; Venditti JM; Schabel FM
    Cancer Treat Rep; 1979 May; 63(5):799-801. PubMed ID: 455319
    [No Abstract]   [Full Text] [Related]  

  • 6. Basic requirements for long-term assays for carcinogenicity.
    Feron VJ; Grice HC; Griesemer R; Peto R; Agthe C; Althoff J; Arnold DL; Blumenthal H; Cabral JR; Della Porta G; Ito N; Kimmerle G; Kroes R; Mohr U; Napalkov NP; Odashima S; Page NP; Schramm T; Steinhoff D; Sugar J; Tomatis L; Uehleke H; Vouk V
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):21-83. PubMed ID: 6935180
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: W. R. Greco et al., Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5327, 1990.
    Sühnel J
    Cancer Res; 1992 Aug; 52(16):4560-1; author reply 4561-5. PubMed ID: 1643649
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: W. R. Greco et al., Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5327, 1990.
    Berenbaum MC
    Cancer Res; 1992 Aug; 52(16):4558-60; author reply 4561-5. PubMed ID: 1643648
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of murine tumor models in cancer treatment research.
    Martin DS; Balis ME; Fisher B; Frei E; Freireich EJ; Heppner GH; Holland JF; Houghton JA; Houghton PJ; Johnson RK
    Cancer Res; 1986 Apr; 46(4 Pt 2):2189-92. PubMed ID: 3948188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental research on the antitumor effectiveness of Bac. intermedius RNAse].
    Kurinenko BM; Sobchuk LI; Khaĭbullina SA; Bulgakova RSh
    Eksp Onkol; 1988; 10(6):54-7. PubMed ID: 3243197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncertainty estimates for low-dose-rate extrapolations of animal carcinogenicity data.
    Guess H; Crump K; Peto R
    Cancer Res; 1977 Oct; 37(10):3475-83. PubMed ID: 908002
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for adult soft tissue sarcoma. Does it work?
    Saeter G
    Acta Orthop Scand Suppl; 1997 Feb; 273():139-44. PubMed ID: 9057605
    [No Abstract]   [Full Text] [Related]  

  • 14. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical designs for experiments in combination therapy.
    Miller I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):151-6. PubMed ID: 4826494
    [No Abstract]   [Full Text] [Related]  

  • 16. Assays for in vitro and in vivo synergy.
    Teicher BA
    Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216
    [No Abstract]   [Full Text] [Related]  

  • 17. [Xenograft of human bronchial squamous cell carcinoma and its sensitivity to therapy].
    Bak M; Sugár J
    Orv Hetil; 1984 Dec; 125(52):3161-4, 3167. PubMed ID: 6549406
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical chemotherapy: historical aspects.
    Goldin A
    Mt Sinai J Med; 1985 Jun; 52(6):419-25. PubMed ID: 3894946
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro.
    Chou TC
    Contrib Gynecol Obstet; 1994; 19():91-107. PubMed ID: 7995057
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antitumor activity of a combination of dimethylnitrosourea and a carbohydrate derivative of nitrosourea (ADEKO) with cyclophosphamide in an experiment].
    Krutova TV; Kondradov AA; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1984; (3):439-45. PubMed ID: 6747090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.